The Benign Prostatic Hyperplasia Treatment Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
What are the Historical Growth Trends in the Benign Prostatic Hyperplasia Treatment Market?
The market size of the global benign prostatic hyperplasia treatment has seen substantial growth recently. The market is projected to increase from $8.23 billion in 2024 to $8.71 billion in 2025, with a compound annual growth rate (CAGR) of 5.9%. Historical growth trends in this market are not linked to any factors or influences.
What are the 2025 Market Projections: Forecasted Size & Growth Rate for the Benign Prostatic Hyperplasia Treatment Industry?
The market size for benign prostatic hyperplasia treatment is predicted to reach $10.83 billion in 2029, with a compound annual growth rate (CAGR) of 5.6%.
Download Your Free Sample of the 2025 Benign Prostatic Hyperplasia Treatment Market Report and Uncover Key Trends Now!
What are the Key Growth Drivers Fueling the Benign Prostatic Hyperplasia Treatment Market?
The key drivers in the benign prostatic hyperplasia treatment market are:
• Rising adoption of minimally invasive procedures
• Increasing number of geriatric patients
• Availability of advanced treatment options
• Growth focus on patient-centric care.
Global Market Segmentation: Identifying Major Benign Prostatic Hyperplasia Treatment Industry Segments
The benign prostatic hyperplasia treatment market covered in this report is segmented –
1) By Treatment: Minimal Invasive Surgery, Invasive Surgery
2) By Therapeutic Class: Alpha Blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Other Therapeutic classes
3) By End User: Home Healthcare, Hospitals And Clinics, Research And Manufacturing
Subsegments:
1) By Minimal Invasive Surgery: Transurethral Resection of the Prostate (TURP), Laser Surgery, Prostatic Urethral Lift, Transurethral Incision of the Prostate (TUIP), Microwave Therapy
2) By Invasive Surgery: Open Prostatectomy, Robotic Prostatectomy
Pre-order the 2025 Benign Prostatic Hyperplasia Treatment Global Market Report for Fast Delivery & Comprehensive Insights!
What are the emerging Trends Shaping the Future of the Benign Prostatic Hyperplasia Treatment Market?
The key trends in the benign prostatic hyperplasia treatment market are:
• The market is witnessing an increasing shift towards the development of targeted therapies.
• The integration of digital health solutions in treatment is becoming a noticeable trend.
• There is a surge in innovation within surgical procedures for treatment.
• The incorporation of 3D imaging for diagnosis is emerging as a significant trend.
Who Are the Top Competitors & Leading Players in the Benign Prostatic Hyperplasia Treatment Market?
Major players in the benign prostatic hyperplasia treatment market are:
• Pfizer Inc.
• Merck And Co Inc
• AbbVie Inc.
• Bayer AG
• Sanofi S.A.
• GlaxoSmithKline Public Limited Company
• Medtronic Public Limited Company
• Mezzion Pharma Co Ltd
• Eli Lilly and Company
• Teva Pharmaceutical Industries Ltd.
• Boehringer Ingelheim
• Boston Scientific Corporation
• Astellas Pharma Inc.
• Olympus Corporation
• Coloplast Group
• Teleflex Incorporated
• Cook Medical Incorporated
• AngioDynamics, Inc.
• HistoSonics Inc
• Urovant Sciences Ltd
• UroGen Pharma Ltd.
• Urologix Inc
• Zenflow Inc
• Butterfly Medical Ltd.
Regional Dominance: Which Area Leads the Global Template Market?
North America was the largest region in the benign prostatic hyperplasia treatment market in 2024
